Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB – Get Free Report)’s stock price crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.00 and traded as high as $0.44. Hemispherx BioPharma shares last traded at $0.41, with a volume of 341,644 shares traded.
Hemispherx BioPharma Price Performance
Hemispherx BioPharma Company Profile
Hemispherx Biopharma, Inc, a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS).
Recommended Stories
- Five stocks we like better than Hemispherx BioPharma
- How to Evaluate a Stock Before Buying
- Hasbro’s Management Made All the Right Calls This Quarter
- Election Stocks: How Elections Affect the Stock Market
- Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
- ESG Stocks, What Investors Should Know
- Power Surge: Utilities Sector’s Resilience Shines
Receive News & Ratings for Hemispherx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.